Theranos

Theranos
Name	Theranos
Fate	Defunct
Founded	0 2003
Founder	Elizabeth Holmes
Defunct	0 2018
Hq location	Palo Alto, California, United States
Industry	Health technology
Key people	Ramesh Balwani

Theranos was a privately held health technology corporation founded in 2003 by Elizabeth Holmes. The company claimed to have revolutionized blood testing by developing proprietary devices that could perform comprehensive tests from very small volumes of blood, such as from a fingerstick. Its promises attracted significant investment from high-profile figures and partnerships with major retailers, but the underlying technology was later revealed to be fraudulent, leading to the company's dramatic collapse and multiple criminal convictions.

History and founding

Elizabeth Holmes, a Stanford University dropout, founded the company in 2003 with the stated mission of making blood testing more accessible and less invasive. Initially named Real-Time Cures, it was soon renamed Theranos, a portmanteau of "therapy" and "diagnosis." Holmes's vision attracted early backing from prominent venture capital firms and individuals, including Tim Draper and the Walton family. The company operated in stealth mode for over a decade, headquartered in Palo Alto, California, a hub for Silicon Valley innovation. During this period, Holmes assembled a board of directors featuring notable statesmen like George Shultz, Henry Kissinger, and James Mattis, which lent considerable credibility to the nascent enterprise.

Technology and Edison device

The company's core claim was its proprietary technology, primarily the "Edison" device, which it asserted could run hundreds of laboratory tests from just a few drops of blood obtained via capillary draw. This contrasted sharply with traditional methods requiring larger venipuncture samples. Theranos stated its technology used microfluidics and chemistry to miniaturize laboratory processes. However, internal concerns were raised by employees like Erika Cheung and Tyler Shultz, grandson of board member George Shultz, regarding the accuracy and reliability of the Edison system. Investigations later revealed the devices produced erroneous results and that the company frequently conducted tests using commercially available analyzers from companies like Siemens Healthineers.

Partnerships and commercial expansion

Capitalizing on its compelling narrative, Theranos secured a landmark partnership with the Walgreens pharmacy chain, launching "wellness centers" in Arizona and California. It also formed an alliance with Cleveland Clinic and pursued a deal with Safeway. A major expansion involved a partnership with Capital Blue Cross to offer tests to plan members. These commercial deals were bolstered by glowing profiles in media outlets like Forbes and The Wall Street Journal, which initially celebrated Holmes as a visionary. The company reached a peak valuation of over $9 billion, making Holmes a celebrated figure on the covers of magazines like Fortune.

Regulatory and legal challenges

Serious regulatory scrutiny began when the Centers for Medicare & Medicaid Services (CMS) inspected the company's laboratory in Newark, California. In 2016, CMS revoked the Clinical Laboratory Improvement Amendments (CLIA) certificate for that lab and banned Holmes from owning or operating any clinical laboratory for two years. This triggered investigations by the U.S. Securities and Exchange Commission (SEC) and the U.S. Attorney's Office for the Northern District of California. The Food and Drug Administration (FDA) had also previously issued warnings about the unapproved use of its nanotainer blood collection device.

Media exposure and downfall

The company's unraveling accelerated following an investigative report by John Carreyrou of The Wall Street Journal in October 2015, which detailed the technology's failures and deceptive practices. This exposé prompted further investigations by federal agencies and led to the voiding of the Walgreens partnership. As lawsuits from investors and partners mounted, including from the Partner Fund Management hedge fund, the company's operations ceased. In 2018, the SEC charged Holmes and former president Ramesh Balwani with "massive fraud," leading to the dissolution of the company.

Impact and legacy

The collapse of Theranos became a seminal case study in corporate fraud and the perils of the "fake it till you make it" culture in Silicon Valley. It prompted increased scrutiny of health technology startups by regulators, media, and investors. The story has been the subject of numerous books, including Bad Blood by John Carreyrou, documentaries like The Inventor: Out for Blood in Silicon Valley, and a Hulu series titled The Dropout. In 2022, Elizabeth Holmes was convicted on multiple counts of wire fraud and conspiracy, and Ramesh Balwani was similarly convicted in a separate trial, both receiving federal prison sentences.

Category:Defunct companies based in California Category:Health technology companies of the United States Category:Corporate scandals